Long enduring response on Teclistamab in a patient with myeloma relapse after allogeneic hematopoietic stem cell transplantation – a case report
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Cellular based therapies, such as bispecific T-cell engagers (TCE), have changed the landscape of myeloma treatment, still less is known about the use of these therapies in patients with prior allogeneic hematopoietic stem cell transplantation (alloHSCT). In this case report, we present a patient with multi-refractory multiple myeloma (MM), who relapsed after alloHSCT and was ultimately successfully treated with teclistamab, a BCMA-directed TCE, and we discuss underlying immunological mechanisms, that might have contributed to a long enduring treatment response.
